Combined inhaled salbutamol and mannitol therapy for mucus hyper-secretion in pulmonary diseases

Hui Xin Ong, Daniela Traini, Giulia Ballerin, Lucy Morgan, Lachlan Buddle, Santo Scalia, Paul M. Young*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)

Abstract

This study focuses on the co-engineering of salbutamol sulphate (SS), a common bronchodilator, and mannitol (MA), a mucolytic, as a potential combination therapy for mucus hypersecretion. This combination was chosen to have a synergic effect on the airways: the SS will act on the β2-receptor for relaxation of smooth muscle and enhancement of ciliary beat frequency, whilst mannitol will improve the fluidity of mucus, consequently enhancing its clearance from the lung. A series of co-spray-dried samples, containing therapeutically relevant doses of SS and MA, were prepared. The physico-chemical characteristics of the formulations were evaluated in terms of size distribution, morphology, thermal and moisture response and aerosol performance. Additionally, the formulations were evaluated for their effects on cell viability and transport across air interface Calu-3 bronchial epithelial cells, contractibility effects on bronchial smooth muscle cells and cilia beat activity using ciliated nasal epithelial cells in vitro. The formulations demonstrated size distributions and aerosol performance suitable for inhalation therapy. Transport studies revealed that the MA component of the formulation enhanced penetration of SS across the complex mucus layer and the lung epithelia cells. Furthermore, the formulation in the ratios of SS 10-6 and MA 10-3 M gave a significant increase in cilia beat frequency whilst simultaneously preventing smooth muscle contraction associated with mannitol administration. These studies have established that co-spray dried combination formulations of MA and SS can be successfully prepared with limited toxicity, good aerosol performance and the ability to increase ciliary beat frequency for improving the mucociliary clearance in patients suffering from hyper-secretory diseases, whilst simultaneously acting on the underlying smooth muscle.

Original languageEnglish
Pages (from-to)269-280
Number of pages12
JournalAAPS Journal
Volume16
Issue number2
DOIs
Publication statusPublished - Mar 2014
Externally publishedYes

Keywords

  • cilia responce
  • epithelia transport
  • lung delivery
  • mannitol
  • salbutamol
  • smooth muscle responce

Fingerprint

Dive into the research topics of 'Combined inhaled salbutamol and mannitol therapy for mucus hyper-secretion in pulmonary diseases'. Together they form a unique fingerprint.

Cite this